- Antibody drug conjugates (ADCs), which combine the targeting capability of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents, are becoming essential in cancer therapy across North America—particularly in the United States, Canada, and Mexico—due to their precision, reduced side effects, and growing clinical success
- The rising demand for ADCs is primarily driven by increasing cancer incidence, heightened focus on personalized medicine, and expanded investments in oncology research and clinical development across the region
- U.S. dominated the North America antibody drug conjugates (ADC) market with the largest revenue share of 82.8% in 2024, supported by a highly advanced healthcare system, strong biopharmaceutical R&D investment, and a high concentration of major pharmaceutical companies actively developing and commercializing ADC therapies
- Canada is expected to witness fastest growth in North America antibody drug conjugates (ADC) market, supported by rising cancer awareness, enhanced healthcare access, and growing collaboration in cross-border clinical research
- The breast cancer segment dominated the antibody drug conjugates (ADC) market in North America with a market share of 40.2% in 2024, led by the clinical success of HER2-targeted ADCs and continued advancements in treatment for aggressive breast cancer subtypes such as triple-negative breast cancer
